Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Fig. 1

Participant flowchart. From a screening of 234 patients, 24 were enrolled as patients with CTLI. The study was composed of autologous bone marrow mononuclear cell group (auto-BM-MNC) (n = 7), allogenic Wharton jelly-derived mesenchymal stem cells group (allo-WJ-MSCs) (n = 7), and a placebo group (n = 10), as depicted on the left side. Reasons of screening failure were values of TcPO2 > 30 mmHg (n = 108), disinterest in the study (n = 45), death (n = 22), amputation (n = 16), non-diabetic participants (n = 12) and age (n = 7), as depicted on the right side

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512